JPMorgan analyst Eric Joseph lowered the firm’s price target on Beam Therapeutics (BEAM) to $46 from $48 and keeps an Overweight rating on the shares. The firm established a December 2026 (price target(from December 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Private Markets: Dyna Robotics raises $120M from Nvidia, Amazon
- Cathie Wood Invests $37M into Biotech Stocks, Trims Stake in KTOS, TEM, and ROKU Stocks
- Cathie Wood’s ARK Investment buys 491K shares of Beam Therapeutics today
- Cathie Wood Bets on AMD, Bullish, and Figma; Trims Tempus AI, Roku
- Beam Therapeutics: Strong Buy Rating Backed by Advancements in Genetic Medicine Programs